Charmingly Eccentric: SELLaS Life Sciences Presents Final Data from Phase 1/2 Study of Galinpepimut-S in Combination with Keytruda for Advanced Ovarian Cancer
Charmingly Eccentric: SELLAS Life Sciences Group, Inc. to Present Final Data Exciting News from SELLAS Life Sciences Charmingly eccentric, full of personality, and designed for maximum reader engagement, SELLAS Life Sciences Group, Inc. has announced that they will be presenting the topline clinical data from the final analysis of the Phase 1/2 clinical trial. This…